Skip to Content

Generic Trelstar Availability

Trelstar is a brand name of triptorelin, approved by the FDA in the following formulation(s):

TRELSTAR (triptorelin pamoate - injectable;intramuscular)

  • Manufacturer: ALLERGAN SALES LLC
    Approval date: June 15, 2000
    Strength(s): EQ 3.75MG BASE/VIAL [RLD]
  • Manufacturer: ALLERGAN SALES LLC
    Approval date: June 29, 2001
    Strength(s): EQ 11.25MG BASE/VIAL [RLD]
  • Manufacturer: ALLERGAN SALES LLC
    Approval date: March 10, 2010
    Strength(s): EQ 22.5MG BASE/VIAL [RLD]

Has a generic version of Trelstar been approved?

No. There is currently no therapeutically equivalent version of Trelstar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trelstar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Sustained and controlled release of water insoluble polypeptides
    Patent 5,776,885
    Issued: July 7, 1998
    Inventor(s): Orsolini; Piero & Mauvernay; Rolland-Yves & Deghenghi; Romano
    Assignee(s): Debio Recherche Pharmaceutique SA
    A pharmaceutical composition for the sustained release of a peptide wherein the composition includes a polylactide polymer, a polymer of lactic acid and glycolic acid, or a mixture of such polymers and a therapeutically active peptide in the form of its pamoate, tannate or stearate salt. The composition when placed in an aqueous physiological environment releases the peptide in a continuous manner for a period of at least about one week.
    Patent expiration dates:
    • July 7, 2015
      Drug product
    • July 7, 2015


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.